EDSA (Edesa Biotech) EPS without NRI: $-1.34 (TTM As of Mar. 2026)


EDSA Edesa Biotech Inc EDSA
26 GF Score
Price $7.45
! 2 Warning Signs
View Full Analysis

What is Edesa Biotech EPS without NRI?

Edesa Biotech EDSA -3.23% 26 EPS without NRI is $-1.34 as of Mar. 2026. GuruFocus rates EDSA with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 1,170 Biotechnology companies, Edesa Biotech ranks better than 82.39% on this metric.

Edesa Biotech's earnings per share without non-recurring items for the three months ended in Mar. 2026 was $-0.49. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.34.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 46.80% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 29.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Edesa Biotech's EPS without NRI or its related term are showing as below:

EDSA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -94.6   Med: 22.05   Max: 71.4
Current: 46.8

During the past 13 years, Edesa Biotech's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 71.40% per year. The lowest was -94.60% per year. And the median was 22.05% per year.

EDSA's 3-Year EPS without NRI Growth Rate is ranked better than
82.39% of 1170 companies
in the Biotechnology industry
Industry Median: 16.75 vs EDSA: 46.80

Edesa Biotech's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.49. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.34.

Edesa Biotech's EPS (Basic) for the three months ended in Mar. 2026 was $-0.49. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.34.


Edesa Biotech  (NAS:EDSA) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Edesa Biotech EPS without NRI Related Terms


Edesa Biotech EPS without NRI Historical Data

* Premium members only.

The historical data trend for Edesa Biotech's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edesa Biotech EPS without NRI Chart

Edesa Biotech Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.69 -8.36 -2.93 -1.92 -1.26

Edesa Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.30 -0.25 -0.32 -0.28 -0.49

EDSA vs ACET, HRTX, ENTX: EPS without NRI Comparison

For the Biotechnology subindustry, Edesa Biotech's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Edesa Biotech PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Edesa Biotech's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Edesa Biotech's PE Ratio without NRI falls into.


EDSA
26GF Score
Edesa Biotech Inc EDSA
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Edesa Biotech EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $-1.34 mean?
Edesa Biotech (EDSA) has a EPS without NRI of $-1.34 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Edesa Biotech and its competitors. According to the industry distribution chart, Edesa Biotech ranks #206 out of 1170 companies in the Biotechnology industry, placing it in the top 17.6%.
Is Edesa Biotech's EPS without NRI too high?
Edesa Biotech's current EPS without NRI is $-1.34. Based on the distribution chart, Edesa Biotech ranks #206 out of 1170 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Edesa Biotech has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Edesa Biotech's EPS without NRI compare to ACET and HRTX?
According to the Biotechnology industry distribution chart, Edesa Biotech ranks #206 out of 1170 companies for EPS without NRI. This places Edesa Biotech in the top 18% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 16.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.75, based on 1,170 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Edesa Biotech and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edesa Biotech's current EPS without NRI is $-1.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edesa Biotech stock overvalued right now?
Edesa Biotech (EDSA) has a current EPS without NRI of $-1.34. The current EPS without NRI is $-1.34. Edesa Biotech's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Edesa Biotech (EDSA), the current EPS without NRI is $-1.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Edesa Biotech Business Description

Address 100 Spy Court, Markham, ON, CAN, L3R 5H6
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
26GF Score

Get the complete analysis for EDSA

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.45
Price